Theranostics Market Size Worth USD 8,640.97 million by 2034 | CAGR: 15.5%
The global theranostics market is poised for significant expansion, fueled by advancements in personalized medicine and the rising demand for targeted therapies. According to industry analysis, the market was valued at USD 2,049.68 million in 2024 and is projected to grow to USD 2,362.26 million in 2025, reaching an impressive USD 8,640.97 million by 2034, at a compound annual growth rate (CAGR) of 15.5% during the forecast period of 2025–2034.
Market Overview
Theranostics, an innovative approach combining diagnostic imaging with targeted therapy, is rapidly transforming healthcare by enabling precision treatment for complex diseases such as cancer, cardiovascular disorders, and neurological conditions. The integration of molecular imaging with therapeutic agents allows for accurate disease detection, real-time monitoring, and personalized treatment, significantly improving patient outcomes.
The market is witnessing rising adoption across oncology, cardiology, and neurology sectors, driven by increasing incidence of chronic diseases, technological advancements in radiopharmaceuticals, and growing preference for minimally invasive procedures.
Request Free Sample:
Key Market Trends
-
Rising Adoption of Radiotheranostics: The demand for radiolabeled therapeutic agents is accelerating, particularly in oncology for prostate, neuroendocrine, and breast cancers.
-
Advancements in Molecular Imaging: PET/CT and SPECT technologies are enhancing diagnostic precision, driving demand for integrated theranostic solutions.
-
Growth in Companion Diagnostics: The development of companion diagnostic tests is fostering personalized treatment strategies, ensuring optimal drug efficacy.
-
Increasing Investments in R&D: Pharmaceutical and biotechnology companies are investing heavily in theranostics research, driving innovation in targeted therapies.
-
Emergence of AI & Big Data: The use of AI-driven analytics in image interpretation and treatment planning is further refining theranostic applications.
Market Size & Forecast (2025–2034)
-
2024: USD 2,049.68 million
-
2025: USD 2,362.26 million
-
2034: Expected to reach USD 8,640.97 million
-
CAGR (2025–2034): 15.5%
Key Market Opportunities
-
Expansion of theranostic applications beyond oncology into cardiology, neurology, and infectious diseases.
-
Growing partnerships between diagnostic companies, pharmaceutical giants, and research institutions.
-
Increased regulatory support for the approval of novel radiotheranostic agents.
-
Rising healthcare investments in emerging markets, particularly in Asia-Pacific and Latin America.
Market Scope
The theranostics market spans radiopharmaceuticals, imaging agents, companion diagnostics, and targeted therapeutics. While oncology remains the dominant segment, other areas such as cardiovascular and neurological disorders are expected to witness substantial growth. Geographically, North America leads the market, followed by Europe, while Asia-Pacific is projected to exhibit the fastest growth rate during the forecast period.
